Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · Real-Time Price · USD
1.080
+0.010 (0.93%)
May 2, 2025, 4:00 PM EDT - Market closed
Acumen Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Cash & Equivalents | 35.63 | 66.89 | 130.1 | 122.16 | 43.78 | Upgrade
|
| Short-Term Investments | 135.93 | 176.64 | 47.5 | 72.08 | - | Upgrade
|
| Cash & Short-Term Investments | 171.56 | 243.52 | 177.61 | 194.24 | 43.78 | Upgrade
|
| Cash Growth | -29.55% | 37.11% | -8.56% | 343.70% | 568.15% | Upgrade
|
| Accounts Receivable | - | - | - | - | 0.11 | Upgrade
|
| Other Receivables | 0.63 | 0.4 | 0.11 | 0.1 | - | Upgrade
|
| Receivables | 0.63 | 0.4 | 0.11 | 0.1 | 0.11 | Upgrade
|
| Inventory | 0.16 | 0.1 | 0.2 | 0.08 | 0.09 | Upgrade
|
| Prepaid Expenses | 0.86 | 0.81 | 1.11 | 1.51 | 0.01 | Upgrade
|
| Other Current Assets | 5.1 | 1.79 | 1.31 | 2.73 | 0.45 | Upgrade
|
| Total Current Assets | 178.31 | 246.62 | 180.33 | 198.66 | 44.43 | Upgrade
|
| Property, Plant & Equipment | 0.34 | 0.5 | 0.27 | 0.04 | - | Upgrade
|
| Long-Term Investments | 59.97 | 62.55 | 15.84 | 31.62 | - | Upgrade
|
| Other Long-Term Assets | 0.38 | 0.45 | 0.15 | 0.01 | - | Upgrade
|
| Total Assets | 238.99 | 310.13 | 196.59 | 230.33 | 44.43 | Upgrade
|
| Accounts Payable | 5.65 | 1.38 | 1.64 | 1.09 | 0.53 | Upgrade
|
| Accrued Expenses | 21.6 | 10.51 | 5.94 | 3.86 | 0.33 | Upgrade
|
| Current Portion of Leases | 0.13 | 0.87 | 0.11 | - | - | Upgrade
|
| Other Current Liabilities | 0.23 | 0.21 | 0.13 | 0.2 | 5.5 | Upgrade
|
| Total Current Liabilities | 27.61 | 12.97 | 7.81 | 5.15 | 6.37 | Upgrade
|
| Long-Term Debt | 29.42 | 29.9 | - | - | - | Upgrade
|
| Long-Term Leases | 0.15 | 0.28 | - | - | - | Upgrade
|
| Total Liabilities | 57.18 | 43.15 | 7.81 | 5.15 | 6.37 | Upgrade
|
| Common Stock | 0.01 | 0.01 | 0 | 0 | - | Upgrade
|
| Additional Paid-In Capital | 506.99 | 489.45 | 359.95 | 352.98 | 8.37 | Upgrade
|
| Retained Earnings | -325.13 | -222.8 | -170.43 | -127.57 | -26.97 | Upgrade
|
| Comprehensive Income & Other | -0.05 | 0.31 | -0.75 | -0.23 | - | Upgrade
|
| Total Common Equity | 181.82 | 266.97 | 188.78 | 225.18 | -18.59 | Upgrade
|
| Shareholders' Equity | 181.82 | 266.97 | 188.78 | 225.18 | 38.06 | Upgrade
|
| Total Liabilities & Equity | 238.99 | 310.13 | 196.59 | 230.33 | 44.43 | Upgrade
|
| Total Debt | 29.7 | 31.05 | 0.11 | - | - | Upgrade
|
| Net Cash (Debt) | 201.82 | 275.03 | 193.34 | 225.86 | 43.78 | Upgrade
|
| Net Cash Growth | -26.62% | 42.25% | -14.40% | 415.92% | 568.15% | Upgrade
|
| Net Cash Per Share | 3.36 | 5.66 | 4.76 | 11.26 | 104.45 | Upgrade
|
| Filing Date Shares Outstanding | 60.57 | 60.08 | 41.03 | 40.47 | 0.42 | Upgrade
|
| Total Common Shares Outstanding | 60.09 | 57.91 | 41.03 | 40.47 | 0.42 | Upgrade
|
| Working Capital | 150.7 | 233.64 | 172.52 | 193.51 | 38.06 | Upgrade
|
| Book Value Per Share | 3.03 | 4.61 | 4.60 | 5.56 | -44.35 | Upgrade
|
| Tangible Book Value | 181.82 | 266.97 | 188.78 | 225.18 | -18.59 | Upgrade
|
| Tangible Book Value Per Share | 3.03 | 4.61 | 4.60 | 5.56 | -44.35 | Upgrade
|
Updated Mar 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.